This article is more than 5 years old. Information may no longer be current.
Avedro implements reimbursement pathway for cross-linking products
Click Here to Manage Email Alerts
LOS ANGELES — Avedro has undertaken an initiative to secure coverage and support reimbursement for its cross-linking system for treatment of keratoconus and corneal disease.
“Our plan going forward is to expand the market for keratoconus,” Reza Zadno, president and CEO of Avedro, told Healio.com/OSN during the Ophthalmology Innovation Summit here. Securing such reimbursement would advance that goal by allowing greater patient access to the treatment.
The KXL system, Photrexa 0.146% (riboflavin 5’-phosphate ophthalmic solution) and Photrexa Viscous 0.146% (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) are FDA approved for treatment of progressive keratoconus and corneal ectasia.
As part of the initiative, the company will launch the Avedro Reimbursement Customer Hub program, which will include a hotline, a patient assistance program and a prescription assistance program, according to a company press release.
Zadno said the company is also expanding into the refractive market but “not competing with LASIK.”
Disclosure: Zadno reports he is president and CEO of Avedro.